Document is current
Any future updates will be listed below
-
Authors
Borcoman, Edith https://orcid.org/0000-0002-5393-5657
Cabarrou, Bastien
Francisco, Miguel
Bigot, Frédéric
Ghiringhelli, François https://orcid.org/0000-0002-5465-8305
Vansteene, Damien https://orcid.org/0000-0002-4440-0626
Legrand, François
Halladjian, Maral
Dupain, Célia
Le Saux, Olivia https://orcid.org/0000-0002-7815-323X
Coutzac, Clelia https://orcid.org/0000-0002-8347-6957
Borel, Christian
Chaltiel, Raphael
You, Benoit https://orcid.org/0000-0002-3177-8857
Gomez-Roca, Carlos
Cousin, Sophie
Coquan, Elodie
Lambert, Aurélien https://orcid.org/0000-0001-9990-1201
Saada-Bouzid, Esma
Durando, Xavier
Saint-Ghislain, Mathilde
Frige, Gianmaria https://orcid.org/0000-0003-3253-7091
Guerini-Rocco, Elena
Tonini, Maria Manuela
Bièche, Ivan
Castel-Ajgal, Zahra
Marret, Grégoire
Sablin, Marie-Paule
Jeannot, Emmanuelle https://orcid.org/0000-0002-4851-7450
Andre, Fabrice https://orcid.org/0000-0001-5795-8357
Filleron, Thomas
Jimenez, Marta https://orcid.org/0000-0002-4233-8478
Mazzarella, Luca https://orcid.org/0000-0002-4043-3279
Servant, Nicolas https://orcid.org/0000-0003-1678-7410
Kamal, Maud
Le Tourneau, Christophe https://orcid.org/0000-0001-9772-4686
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 21 May 2025
First Online: 30 June 2025
Competing interests
: E.B. received honoraria from Eisai, Merck Sharp and Dohme (MSD), Sandoz and Amgen and meetings/travel grants and nonfinancial support from Daiichi Sankyo, Eisai, Amgen, Sandoz, MSD, Bristol Myers Squibb (BMS), Novartis, Pfizer and Roche and has consulted for Egle Tx, all outside of the submitted work. F.G. received fees for oral communication from Eli Lilly, Sanofi, BMS, AstraZeneca and Amgen, received funding for clinical trials from AstraZeneca, received travel grants from Roche France, Amgen and Servier and is an advisory board member for Merck Serono, Amgen, Roche France and Sanofi, all outside of the submitted work. O.L.S. reports honoraria from MSD and Clovis and travel/accommodation/expenses from Eisai. C.C. participated on advisory boards from Amgen, BMS, Merck Serono, Pierre Fabre and Servier and received personal fees from BMS, Merck Serono, Pierre Fabre and Servier and institutional fees from Amgen, AstraZeneca, BMS, Daiichi Sankyo, MSD and ImCore Roche Genentech. C.B. participated on advisory boards from AstraZeneca, Merck Serono and MSD and received personal fees from AstraZeneca, BMS, Merck Serono and MSD. E.S.-B. participated on advisory boards and received travel expenses from MSD and Merck Serono. C.G.-R. has previously received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from BMS, F. Hoffmann-La Roche, Genentech, Foundation Medicine and Pierre Fabre, has supported or attended meetings and/or travel for MSD and F. Hoffmann-La Roche and has participated on a data safety monitoring board or advisory board for Macomics and Pharmamar. E.G.-R. has relevant relationships (advisory fees, honoraria, travel accommodation and expenses, grants and/or nonfinancial support) with AstraZeneca, Exact Sciences, GSK, Illumina, MSD, Novartis, Roche, Sophia Genetics and Thermo Fisher Scientific, unrelated to the current work. T.F. reports receiving personal fees from Jansen outside the submitted work and institutional fees from Roche and Lilly outside the submitted work. C.L.T. participated on advisory boards from MSD, BMS, Merck, AstraZeneca, Celgene, Seattle Genetics, Roche, Novartis, Rakuten, Nanobiotix and GSK. The other authors declare no competing interests.
